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Introduction
The relationship between mental disorder and mortality has
been examined in hundreds of studies worldwide in the past
few decades, although some of the studies go back at least 150
years [1,2]. One of the mental disorders that has been exam-
ined in great depth is depression [3•]. Most of the studies
exploring the relationship between depression and mortality
have focused on whether mortality rates in people with a
mental disorder are higher than in other populations. Rela-
tively few studies have examined the processes through which
mental disorders influence mortality risks. This research has
resulted in an accumulation of evidence showing that sub-
jects with depression have increased mortality rates. Several
hypotheses have been developed to explain this phenome-
non. However, the evidence supporting these hypotheses dif-
fers greatly for each one.
In this article, we first will summarize the results of epide-
miologic research examining the relationship between
depression and mortality. We then will describe the hypothe-
ses that have been posed to explain increased mortality in
depression and the research supporting these hypotheses.
Are Mortality Rates Increased 
in Subjects with Depression?
The question of whether depression increases mortality
rates has been examined in community studies [4•], in
studies comparing patients treated for depression in the
general population [3•], and in studies of medical patients,
including depressed patients with heart diseases [5–8],
patients who have had stroke [9], patients with a life-
threatening illness [10], and elderly patients with varying
illnesses [11–13].
Recently, we did a meta-analysis of prospective studies
examining mortality rates in subjects with depression com-
pared to the rest of the population [4•]. A systematic
search of the literature in the most important bibliographic
databases resulted in 25 prospective studies, reporting on a
random sample from a community and comparing mortal-
ity rates in depressed to nondepressed subjects. These stud-
ies included 106,628 subjects, of who 6416 were depressed.
The overall relative risk (RR) of dying in depressed subjects
was found to be 1.81 (95% CI, 1.58–2.07) compared with
nondepressed subjects. Because the set of studies was sig-
nificantly heterogeneous, we excluded the studies that con-
tributed most to the heterogeneity until a homogeneous
set of studies was obtained. The relative risk of the resulting
set of studies (three studies were excluded) was found to be
1.65 (95% CI, 1.51–1.81).
In our meta-analysis, we included studies examining
subjects with major depressive disorder according to diag-
nostic criteria and studies of subjects with subthreshold
forms of depression. Subthreshold depression could be
operationalized by scoring above a cut-off point on a self-
rated depression questionnaire, by having one or more
basic characteristics of depression (mood problems for 2
weeks), or by meeting criteria for minor depression as
operationalized in the Diagnostic and Statistical Manual
IV, the International Classification of Diseases, 10th Revi-
sion, or the Research Diagnostic Criteria. We did not find
any indication that the relative risk in subjects with major
depression (1.54; 95% CI, 0.96, 2.47) was higher than in
subjects with subthreshold forms of depression (1.65; 95%
CI, 1.39, 1.96). These results are supported by several other
Several factors have been proposed to explain the relation-
ship between excess mortality and depressive disorders. 
These include mechanisms such as increased suicide rates, 
hazardous health behavior (smoking, alcohol use, unhealthy 
eating), psychologic reactions to developing a medical ill-
ness, biological dysregulations (hyperactivity of the hypo-
thalamic pituitary adrenal, neuro-immune dysregulation, 
sympathoadrenergic dysregulation), and noncompliance 
with medical treatment. The evidence supporting the role 
of each of these mechanisms in excess mortality varies con-
siderably. The causal direction in most of the mechanisms is 
not clear. It is possible that the explanatory factors, such as 
smoking, compliance, or biological mechanisms, cause 
depression, or that depression causes these factors, or that 
both are explained by a third, underlying factor. We will 
summarize the evidence supporting these mechanisms, and 
propose options for possible interventions aimed at reduc-
ing the increased risk of dying.
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mortality and depression [3•,14,15••,16].
In some community studies, subjects with major
depression and subjects with subthreshold depression
were examined [17•,18,19], and direct comparisons
between these two populations within each of these stud-
ies confirm that there is no strong evidence of a significant
difference in mortality rates.
Some studies found indications that the increased risk of
death especially is present in men, but is not present or is less
so in women [17•,19–21]. In our meta-analysis, we also
found support for this difference between men and women.
The relative risk of dying was 2.25 (95% CI, 1.90, 2.67) in
men, compared to 1.62 (95% CI, 1.37, 1.92) in women. In a
multivariate metaregression analysis in which we controlled
for several possible confounding variables, the difference
between men and women remained considerable.
Depressive disorder is not the only mental disorder
with increased mortality rates. In a large systematic review
of more than 150 studies, evidence showed that mortality
rates are increased in all mental disorders, including eating
disorders, alcohol and drug dependence and abuse, schizo-
phrenia, bipolar disorders, dysthymia, anxiety disorders,
personality disorders, and major depressive disorders [3•].
It also was found in this review that the highest risks for
premature deaths were found in substance abuse and eat-
ing disorders. However, the risk of death from unnatural
causes is especially high in functional disorders, particu-
larly in schizophrenia and major depression.
Possible Causes of Increased 
Mortality Rates in Depression
On the basis of our meta-analysis, we can calculate the
population-attributable risk of depression. This indicates
the percentage of deaths that can be avoided if the risk fac-
tor (in this case depression) were to be erased altogether.
We found the population-attributable risk to be 7.5 %.
This is considerable when compared to lifestyle factors
[22]. Among these lifestyle factors only tobacco use
(18.1%) and poor diet and lack of physical exercise
(16.6%) result in more deaths than depressive disorders.
Other major lifestyle factors, such as alcohol consumption
(3.5%), score considerably lower than depressive disorder.
However, depression cannot be directly compared to
these lifestyle factors, as there is much more evidence
supporting the causal link between lifestyle factors and
increased mortality. A direct causal relation between
depression and mortality has not been proven, and it is
possible that the increased mortality is not directly
caused by depression. We will describe the most impor-
tant causes of increased mortality in depression that have
been proposed, and the supporting evidence. The most
important mechanisms explaining the relationship
between excess mortality and depression are summarized
in Table 1.
Suicide
There are several behavioral causes of the increased mortal-
ity in depression and suicide is among the most important.
Suicide rates in depressive disorders have been studied for
several decades [23]. Although the risk of suicide has long
been overestimated in depression, a recent meta-analysis
of 47 studies estimated that the lifetime risk of suicide
ranges from 2.2% to 8.6% in patients with depression [24],
compared with less than 0.5% in nondepressed subjects.
The lifetime prevalence was found to be especially large in
patients hospitalized for suicidality (8.6%). The lifetime
prevalence found in mixed inpatient/outpatients with
depression has been found to be 2.2%.
Although suicide is one of the causes of increased mor-
tality in depression, it can explain only a small part of the
overall increased mortality because the incidence of suicide
is low. Most studies examining the correlation between
mortality and depression do not examine differences in
actual causes of death between depressed and nonde-
pressed subjects, and most do not have sufficient statistical
power to examine these differences. However, there are
some exceptions. In a well-designed longitudinal study of
elderly people living in the community in the Netherlands,
in which 124 subjects with minor or major depression
died during 50 months follow-up, only one died because
of suicide [17•]. And in a large survey in the United States
among almost 46,000 households, it was found that
among 223 depressed subjects who died, only two died
because of suicide [20].
These figures must be interpreted with caution, because
it is known that many suicides are not registered as such in
the official statistics. Nonetheless, suicide can never
explain more than only a small part of the increased mor-
tality rates in depressed patients.
Table 1. Possible causes of 
increased mortality in depression
 Increased suicide rates in depressed patients
 More hazardous health behaviors in depressed patients
  Tobacco use
  Unhealthy eating habits
  Alcohol use
  Less physical activity
  Hazardous behavior such as dangerous driving
 Depression is a psychologic reaction to medical illnesses* 
 Biological dysregulations
  Hyperactivity of the hypothalamic pituitary adrenal
  Neuro-immune dysregulation
  Sympatho-adrenergic dysregulation
  "Vascular" depression (in the elderly)
 Less compliance with treatment in depressed patients
*Excess mortality is not caused by depression, but by the illness.
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Another mechanism that is assumed to be responsible for
increased mortality in depression is hazardous health
behavior. It has been established that patients with depres-
sion smoke more, stop smoking less easily, have more
unhealthy eating habits, drink more alcohol, have less
physical activity, and engage in more hazardous behavior,
such as dangerous driving.
It has been known for several decades that smokers are
more neurotic than nonsmokers [25–27]. These early stud-
ies also showed that smokers who ceased smoking were
less neurotic, less depressed, and less anxious than those
who did not succeed in their attempt to quit. Several more
recent studies have shown that there also is a relationship
between smoking and depressive disorders that meet rigor-
ous criteria. Compared with nonsmokers, smokers often
have had a depressive disorder in their lives [28–30]. This
relationship between depressive disorders and smoking
has been shown to exist as early as in adolescence [31].
There also is evidence that the likelihood of entering a new
episode of major depression is greater among smokers
than among nonsmokers [30,32]. Additionally, research
has shown smokers with a history of major depression fail
their attempts at smoking cessation more often than other
smokers [28,30]. When smokers with a history of depres-
sion stop, they have a significantly increased risk of devel-
oping a new depressive disorder as compared with smokers
without a history of depression [32].
Although the evidence clearly points to a strong rela-
tionship between tobacco use and depression, there is little
evidence about the exact nature of this relationship and
causal directions. It has been suggested that depression
may be caused by smoking through neurochemical
changes [33••], that depression leads to smoking by
increasing the likelihood that individuals will self-medi-
cate negative feelings with nicotine [27], and that depres-
sion and smoking are caused by common physical or
psychologic factors that independently increase the risk of
both conditions [33••].
Other Hazardous Health Behaviors
Tobacco use is only one of the unhealthy lifestyle factors
that are more prevalent in patients with depressive disor-
der than in other subjects. It has been shown repeatedly
that patients with depression more often drink too much
alcohol [34–37], although there are indications that this is
not true in elderly subjects [17•,38]. There also is some evi-
dence that problem drinking has a negative effect on prog-
nosis of depressive disorder.
Several other studies found that depressive disorder is
associated with body mass index [39,40] and obesity [41],
especially among subjects with severe obesity. Depressive
disorders also have been found to be associated with lower
physical activity [17•], and with a larger number of fatal
accidents [42].
The relationship between these lifestyle factors and
depression also can work in the three directions cited ear-
lier: lifestyle factors may cause depression, depression may
cause differences in lifestyle, or both may be the result of
one or more independent factors.
Mortality in Depressed Patients 
With General Medical Illnesses
As indicated previously, depression has been shown to be
more prevalent in several general medical illnesses, includ-
ing diabetes [43], heart diseases [5–8], cancer [44,45],
stroke [9], arthritis, osteoporosis, Alzheimer’s disease
[46•], and life-threatening illness in general [10]. It has
been concluded that the prevalence rates of depression
increase from 2% to 5% in community settings, to 5% to
10% in primary care, and to 6% to 14% or greater in medi-
cal and/or surgical patients [47–49].
It has been suggested that some patients develop depres-
sive symptoms as a psychologic reaction to these illnesses,
and that the increased risk of mortality is not caused by
depression, but because of the illnesses that also cause the
depressive symptoms [50]. In these cases, getting an illness is
considered to be an important life event. These psychologic
reactions to illnesses cannot explain all increased mortality. It
also has been shown that subjects with depression also have
an increased risk of developing new general medical ill-
nesses, and this has been shown especially for cardiovascular
disease [51–53] and diabetes [54,55].
Additionally, there is evidence that the prognosis of
patients with depression is in many cases worse than the
prognosis of patients without depression, such as in
patients with myocardial infarction [6]. However, this
could be explained by the phenomenon that illnesses with
a poor prognosis are more depressing than less serious
conditions [56••].
Depression and Biological Dysregulations
Another possible explanation for the association between
depression and excess mortality is biological, occurring
through neuroendocrine and autonomic dysregulation.
Hyperactivity of the hypothalamic pituitary adrenal
(HPA) axis frequently has been established in patients with
depression [57,58]. Through insufficient negative feedback of
the glucocorticoid receptors in the hippocampus and the
hypothalamic paraventricular nucleus [58], excess production
of hypothalamic CRH leads to higher hypophysial adrenocor-
ticotropic hormone release, which in turn causes higher
blood cortisol levels [59]. Hypercortisolemia is associated
with insulin resistance and accumulation of intra-abdominal
fat [60]. The combination of “upper-body obesity,” diabetes,
hypertension and dyslipidemia, also called “deadly quartet,”
is associated with a significantly higher risk of myocardial inf-
arction and stroke [61]. Through lower bone density, hyper-
cortisolemia also is associated with an increased likelihood of
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PHA axis abnormalities precede affective disorder, or result
from chronic stress, traumatization, and depression. Genetic
studies have shown that polymorphisms in the glucocorticoid
receptors are associated with the occurrence of affective disor-
ders, [58,63,64] and healthy family members of patients with
depression have been shown to have HPA axis overactivity
[64]. Therefore, HPA axis abnormalities may participate in the
development of depressive symptoms and in the occurrence
of numerous medical conditions.
A second pathogenetic mechanism, possibly explain-
ing the association between depression and excess mortal-
ity, is neuro-immune dysregulation. Patients with
depression show higher levels of pro-inflammatory cyto-
kines such as interleukins (IL) IL-1 and IL-6, C-reactive
protein, and α-1 antichymotrypsin [65,66]. These are asso-
ciated with hypercortisolemia, [67] myocardial infarction,
and stroke [68–71]. The temporal associations between
depression and neuro-immune dysregulation still must be
elucidated because low doses of endotoxins have been
shown to cause symptoms of depression, anxiety, and cog-
nitive disturbances in healthy volunteers [72,73].
A third mechanism is sympathoadrenergic dysregula-
tion. Depression is associated with increased noradrena-
line levels [68], and autonomic hyperactivity leading to
reduced heart rate variability and an increase in coronary
events [74,75•] Through autonomic dysregulation, upreg-
ulation of platelet serotonin receptors and increased intra-
cellular calcium mobilization, platelet aggregation and
thrombo-embolic processes also are enhanced [75•].
In the elderly, a specific subtype of vascular depression
is distinguished with psychomotor retardation, loss of
interest, a decrease in functional abilities, and vegetative
symptoms. Patients are found to have cerebral (frontostri-
atal) white matter lesions most likely related to microvas-
cular pathology, which also may affect longevity [76,77].
All of these biological mechanisms are linked to
depression and are associated with various somatic disor-
ders. However, the direction of these mechanisms is
unclear. Again, it may be possible that these mechanisms
cause the depression directly, that depression causes these
mechanisms, or that the depression and the mechanisms
are caused by a third factor.
Compliance with Medical Treatment
Another possible explanation for the increased mortality in
depressed patients with general medical disorders is that com-
pliance with treatment is less optimal than in other patients.
There is ample support for this hypothesis in various patient
groups such as patients with HIV [78], patients with cancer
[79], and elderly patients with coronary artery disease [80]. A
recent meta-analysis of the literature concluded that, com-
pared with nondepressed patients, the odds are three times
greater that patients with depression will be noncompliant
with medical treatment recommendations [81].
Why depression affects adherence is unclear. It has been
suggested that reduced adherence is related to other factors,
such as poor social support, increased functional impair-
ment, heightened sensitivity to physical discomforts, and
impaired attention span, concentration, and memory. Each
of these factors has been shown to be related to depression
and to reduced compliance [80]. However, the most obvious
explanation is that the depression reduces the motivation to
adhere to a medical treatment.
It also has been suggested that it is not depression that
causes poor adherence, but the behavior of noncompliance
preceding the mood state [82]. More research is needed to
clarify the causal link between depression and compliance.
Does Treatment of Depression Affect Survival?
In the preceding paragraphs, we have described the mecha-
nisms that may explain excess mortality rates in depres-
sion. Because there are several mechanisms that may be
interlinked, excess mortality probably is caused by several
different pathways. Theoretically, there are several different
methods to intervene in these pathways. Although it is
beyond the scope of this article to describe them all, we
will describe some major possible interventions.
First, as most suicides are committed by subjects with
depression, effective suicide prevention programs may
reduce mortality rates in depressed subjects. Generally,
there is little evidence that suicide prevention programs are
effective, mostly because of a lack of randomized con-
trolled trials and small sample sizes [83]. However, there
are some promising interventions, such as long-term lith-
ium treatment [84], and some recent studies show promis-
ing effects of psychosocial interventions [85–87].
Another possibility is to improve lifestyle factors in
patients with depression. Most research in this area has
focused on tobacco use. Several trials have examined the
effects of cognitive behavior therapy in smokers with a life-
time history of major depression [88–91]. Most of these
studies show positive results, although most of the sample
sizes are small and more research in this area is needed.
Comparable approaches could be possible, focusing on
other lifestyle factors.
A recent meta-analysis of studies examining the effects
of interventions aimed at the improvement of medication
adherence showed that this type of intervention has small
to moderate effects [92]. However, only one of the studies
examined by this meta-analysis was aimed at subjects with
depression, and the effect size for this study was small.
Another important research question is whether ade-
quate treatment of depression may affect the risk of mor-
tality. Theoretically, treatment with antidepressant
medication could result in better survival and excess mor-
tality. Tricyclic antidepressants may cause ventricular
arrhythmias and orthostatic hypotension. In medical (car-
dio) and elderly patients these side effects may have sub-
stantial negative consequences [93,94]. However, it is
434 Mood Disordersunlikely that this could be responsible for the excess mor-
tality in depression. Sparsely available earlier studies sug-
gest that adequate treatment of depression may reduce
mortality [95,96]. Antidepressants have been shown to
affect event-free interval in patients who have had MI [97].
One placebo-controlled trial found that 9-year survival
after stroke was significantly better if patients had been
given antidepressants for some time soon after their stroke,
regardless of the presence or absence of depression [98].
Research has shown that antidepressant medication may
directly affect numerous biological parameters. Selective
serotonin re-uptake inhibitors have been shown to nor-
malize platelet aggregation, and may influence cardiovas-
cular risk patterns [99]. Recent research indicates that
antidepressants may help to restore normal functioning of
the HPA axis in individuals with depression [100,101].
However, possible effects on survival have not been shown
consistently. Recently, this idea was investigated more thor-
oughly in two large randomized placebo-controlled trials.
One study of 369 cardiac patients found that sertraline
could safely and effectively be used to treat depression in
patients with acute MI or unstable angina, although it did
not show an improvement in cardiologic parameters [102].
Another study specifically investigated the impact of treat-
ment on 6-months survival in 2481 patients after MI and
found that cognitive behavior therapy, with the addition of
SSRI improved severe depression and social isolation, but
not event-free interval [103].
Psychotherapy or psychosocial interventions aimed at
reducing depression also may influence survival. A meta-
analysis of psychosocial interventions showed that the
addition of psychosocial treatments to standard cardiac
rehabilitation regimens reduced mortality and morbidity,
psychologic distress, and some biological risk factors dur-
ing the first 2 years [104]. Providing psychosocial support
reduces depression, anxiety, and pain in patients with can-
cer, but studies are divided on whether this also increases
survival time [44].
Overall, it can be concluded that interventions aimed at
either of the pathways linking depression and excess mortal-
ity have beneficial effects on a number of clinically relevant
biological and psychologic parameters, but currently it is not
an established fact that survival of patients with depression
can be improved substantially by these measures.
Conclusions
There is little doubt that there is a relationship between
depression and excess mortality. However, the mechanisms
explaining this relationship are less clear. Several behav-
ioral and physical mechanisms have been proposed. The
evidence supporting the role of each of these mechanisms
in excess mortality varies greatly. The causal direction in
most of the mechanisms is not clear. It is possible that the
explanatory factors, such as smoking, compliance, or neu-
robiological dysregulation cause depression. It also is pos-
sible that depression causes these factors, or that both are
explained by a third, underlying factor.
The mechanisms explaining excess mortality in depres-
sion may be interlinked with each other in complex ways.
For example, lifestyle factors may trigger biological vulner-
ability and psychologic reactions to getting an illness and
may increase suicide risk. It also is possible that underlying
pathogenetic mechanisms and genetic polymorphisms
may constitute higher vulnerability for depression and
medical illnesses.
This suggests that excess mortality is a result of complex
interactions between different factors, and depression may
lead to mortality through different pathways.
We must conclude that the relationship between
depression and excess mortality is not yet well understood,
and although several possible mechanisms explaining this
relationship are suggested, more research is needed before
interventions will become available to reduce this
increased risk of death in patients with depression.
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